Stephen M. Simes, BioSante Pharmaceuticals President and CEO, to Present at the BIO Investor Forum
Thursday, October 30 at 8:30 am PDT
LINCOLNSHIRE, Illinois (October 27, 2008) – Stephen M. Simes, president and CEO of BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), will present at the BIO Investor Forum in San Francisco, California. The BIO Investor Forum is a national investor conference featuring leading private and emerging public companies. The meeting attracts sophisticated healthcare venture and private equity investors, buy-side investors and research analysts. In addition, the BIO Investor Forum draws business development executives from leading global pharmaceutical and mature biotechnology companies.
Mr. Simes will discuss, on Thursday, October 30, 2008 at 8:30 PDT, the LibiGel® (testosterone gel) clinical development plan and primary research data indicating the potential size of the U.S. market for BioSante’s LibiGel in the treatment of female sexual dysfunction. A live audio webcast of this presentation may be accessed at biosantepharma.cdmail.biz/Webcasts.php and a replay will be available at the same link for 60 days.
“We are delighted to have the opportunity to participate at this year’s BIO Investor Forum,” said Mr. Simes. “It is particularly rewarding for us to be able to offer information surrounding various aspects of LibiGel®, the lead drug candidate for the treatment of female sexual dysfunction in menopausal women, during this prestigious event.”
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. BioSante’s lead products include LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) for the treatment of female sexual dysfunction (FSD), and Elestrin™ (estradiol gel) developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, currently marketed in the U.S. Also in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3.0 billion. The company also is developing its calcium phosphate technology (CaP) for novel vaccines, drug delivery and aesthetic medicine (BioLook™). Additional information is available online at: biosantepharma.cdmail.biz.
For more information please contact:
Harris D. McKinney, Inc.
The Investor Relations Group
Adam S. Holdsworth / Erica Ruderman
Laura Colontrelle /Janet Vasquez